About us
- >
- About us >
- Information >
- Announcement
2025-07-25
Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease
Energenesis Biomedical announced the successful completion of the Phase I clinical trial for ENERGI-F705PD, an oral investigational drug candidate for Parkinson's disease (PD). The Phase I trial was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug in 24 healthy subjects. The results confirmed the favorable safety and tolerability profile of ENERGI-F705PD and successfully validated its sustained-release oral formulation. Energenesis Biomedical plans to advance ENERGI-F705PD into a Phase II trial to further evaluate its therapeutic efficacy in patients with Parkinson's disease.